Boehringer Ingelheim, GoodRx team to boost access to Humira biosimilars By Paige Minemyer Jul 18, 2024 3:00pm GoodRx Boehringer Ingelheim Drug Prices biosimilars ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by the Veeva Development Cloud, designed to accelerate the global ...

Boehringer Ingelheim sued the U.S. government in an attempt to block a program that gives the Medicare health insurance plan the power to negotiate lower drug prices, joining other drugmakers and ...

Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.

Boehringer Ingelheim has spied an opportunity to seize the holy grail of immuno-oncology: turning cold tumors hot. In return for $10 million upfront and up to $471 million milestones, the German ...

Boehringer Ingelheim also acknowledged the rise of non-communicable and infectious disease, rapidly aging patient populations and healthcare systems strapped by capacity challenges. Reflecting on the ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...